Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Reduction of Tumor Burden Rather Than Off-Target Effects Drives Changes in T-Cell Number and Profile during Prolonged Ibrutinib Treatment in Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

Marzia Palma, MD PhD, Kia Heimersson, Tom A. Mulder, MD, Barbro Näsman-Glaser, Anders Österborg, MD PhD Prof., Håkan Mellstedt, MD PhD

Blood (2018) 132 (Supplement 1): 4421.

https://doi.org/10.1182/blood-2018-99-110236

Published: 2018

Journal Articles

The Novel Tumor Suppressor SAMHD1 Is Differentially Expressed and Partly Regulated By MYC in Peripheral T-Cell Lymphomas (PTCL)

Pedro Farrajota Neves Da Silva, MD, Nikolaos Tsesmetzis, Ioanna Xagoraris, MD, Agata Magdalena Wasik, PhD MSc, Georgia Kokaraki, PhD, Evangelos Tzoras, Anders Österborg, MD PhD Prof., Birgitta Sander, MD PhD, Nikolas Herold, MD PhD, George Rassidakis, MD PhD

Blood (2018) 132 (Supplement 1): 4130.

https://doi.org/10.1182/blood-2018-99-119229

Published: 2018

Journal Articles

Five-Year Follow-up of Safety and Efficacy of a Phase III Randomized Trial of Ofatumumab Therapy Versus Physicians' Choice in Patients with Bulky Fludarabine Refractory Chronic Lymphocytic Leukemia

Udvardy Miklos, Vladimir Strugov, MD, Catharina Lewerin, MD PhD, Sebastian Grosicki, MD PhD, Grzegorz Mazur, MD PhD, Michael Steurer, MD, Marco Montillo, MD, Irina Kryachok, Prof., PhD, Jan Moritz Middeke, MD, Grygoriy Rekhtman, MD, Tommaso Stefanelli, Ghislaine Vincent, Sameera G, PhD, Anders Österborg, MD PhD Prof.

Blood (2018) 132 (Supplement 1): 5569.

https://doi.org/10.1182/blood-2018-99-113295

Published: 2018

Journal Articles

Genetic Basis, Expression Patterns and Clinical Significance of PD-L1 in Peripheral T-Cell Lymphomas (PTCL)

Pedro Farrajota Neves Da Silva, MD, Vassilis Atsaves, PhD, Nikolaos Tsesmetzis, MSc., Georgia Kokaraki, PhD, Anders Österborg, MD PhD Prof., George Rassidakis, MD PhD

Blood (2018) 132 (Supplement 1): 2868.

https://doi.org/10.1182/blood-2018-99-120036

Published: 2018

Journal Articles

Real-World Results on Ibrutinib in Relapsed/Refractory CLL: A 21-Month Follow-up of 95 Swedish Patients Treated in a Compassionate Use Program

Maria Winqvist, MSc, MD, Per-Ola Andersson, MD PhD, Anna Asklid, MD, Karin Karlsson, MD, Claes Karlsson, MD PhD, Birgitta Lauri, MD, Jeanette Lundin, MD PhD Assoc Prof, Mattias Mattsson, MD, Stefan Norin, MD PhD, Anna Bergendahl Sandstedt, MD, Lotta Hansson, Anders Österborg, MD PhD Prof.

Blood (2017) 130 (Supplement 1): 5353.

https://doi.org/10.1182/blood.V130.Suppl_1.5353.5353

Published: 2017

Journal Articles

First-in-Class Oral Small Molecule Against the Tyrosine Kinase ROR1 (KAN0439834) Induced Significant Apoptosis of Chronic Lymphocytic Leukemia Cells

Mohammad Hojjat-Farsangi, MSc, PhD Assist. Prof., Amir Hossein Daneshmanesh, MD PhD, Fariba Mozaffari, MSc, PhD, Lotta Hansson, Jan Vågberg, PhD, Styrbjörn Byström, PhD, Elisabeth Olsson, PhD, Charlotta Löfberg, PhD, Charlotta Carina Norström, PhD, Johan Schultz, PhD, Martin Norin, PhD, Thomas Olin, PhD, Anders Österborg, MD PhD Prof., Ali Moshfegh, PhD, Hakan Mellstedt, MD PhD Prof.

Blood (2017) 130 (Supplement 1): 4320.

https://doi.org/10.1182/blood.V130.Suppl_1.4320.4320

Published: 2017

Journal Articles

Long-Term Treatment with Ibrutinib in Chronic Lymphocytic Leukemia Patients Normalizes CD3 + and CD8 + T Cells and Immune Checkpoints Expression but Gradually Leads to CD4 + T-Cell Depletion

Marzia Palma, MD PhD, Kia Heimersson, Barbro Näsman-Glaser, Håkan Mellstedt, MD PhD, Anders Österborg, MD PhD Prof.

Blood (2017) 130 (Supplement 1): 4322.

https://doi.org/10.1182/blood.V130.Suppl_1.4322.4322

Published: 2017

Journal Articles

Outcome of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First Line Therapy: A Swedish Nation-Wide Study on 1053 Consecutive Patients Treated between 2007 and 2013

Sandra Eketorp Sylvan, MD PhD, Anna Asklid, MD, Hemming Johansson, Jenny Klintman, MD PhD, Jenny Bjellvi, MD, Staffan Tolvgård, MD, Eva Kimby, Stefan Norin, MD PhD, P-O Andersson, MD PhD Prof., Claes Karlsson, MD PhD, Karin Karlsson, MD, Birgitta Lauri, MD, Mattias Mattsson, MD, Anna Bergendahl Sandstedt, MD, Maria Strandberg, MD, Anders Österborg, MD PhD Prof., Lotta Hansson

Blood (2017) 130 (Supplement 1): 1744.

https://doi.org/10.1182/blood.V130.Suppl_1.1744.1744

Published: 2017

NARROW

Reduction of Tumor Burden Rather Than Off-Target Effects Drives Changes in T-Cell Number and Profile during Prolonged Ibrutinib Treatment in Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

The Novel Tumor Suppressor SAMHD1 Is Differentially Expressed and Partly Regulated By MYC in Peripheral T-Cell Lymphomas (PTCL)

Five-Year Follow-up of Safety and Efficacy of a Phase III Randomized Trial of Ofatumumab Therapy Versus Physicians' Choice in Patients with Bulky Fludarabine Refractory Chronic Lymphocytic Leukemia

Genetic Basis, Expression Patterns and Clinical Significance of PD-L1 in Peripheral T-Cell Lymphomas (PTCL)

Real-World Results on Ibrutinib in Relapsed/Refractory CLL: A 21-Month Follow-up of 95 Swedish Patients Treated in a Compassionate Use Program

First-in-Class Oral Small Molecule Against the Tyrosine Kinase ROR1 (KAN0439834) Induced Significant Apoptosis of Chronic Lymphocytic Leukemia Cells

Long-Term Treatment with Ibrutinib in Chronic Lymphocytic Leukemia Patients Normalizes CD3 + and CD8 + T Cells and Immune Checkpoints Expression but Gradually Leads to CD4 + T-Cell Depletion

Outcome of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First Line Therapy: A Swedish Nation-Wide Study on 1053 Consecutive Patients Treated between 2007 and 2013

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only